Healthcare lawyers Bart Walker, Kayla McCann Marty and Alexis Reynolds authored a paper featured in the September 2017 issue of Health Care Law Monthly that explores the regulatory terrain for investors in the field of cosmetic dermatology.
Globally, the dermatology market is projected to increase from $20 billion two years ago, to $33.7 billion by 2022, with much of the revenue coming from such procedures as body contouring, fat-reduction treatments, skin rejuvenation and hair removal. Solid profit margins have given rise to fervent acquisition and investment within the sector, the authors wrote in “A Beautiful Investment: Regulatory Considerations for Investors in Cosmetic Dermatology.”
They noted, however, that investors and practitioners should be cognizant of various regulatory and diligence considerations raised by laws, rules and regulations in several states and their respective medical boards. The paper breaks down several considerations for investors and dermatologists in the broad areas of fraud and abuse and licensure and operational considerations.
All three authors are based in McGuireWoods’ Charlotte office.